

6. Trastoy-Quintela J, Moure-González JD, González-Fernández L, Rey-Noriega C, Rodríguez-Núñez A. Formación multinivel (atención primaria-hospital) mediante simulación con conexión en tiempo real en tiempos de COVID-19. Una herramienta a considerar. *An Pediatr.* 2021;94:259–60.
7. Ikeyama T, Shimizu N, Ohta K. Low-cost and ready-to-go remote-facilitated simulation-based learning. *Simul Healthc.* 2012;7:35–9.

Laura Butragueño Laiseca<sup>a,b,\*</sup>, Anna Zanin<sup>c</sup>,  
Jesús López-Herce Cid<sup>a,b,d</sup>, Santiago Mencía Bartolomé<sup>a,b,d</sup>

<sup>a</sup> Servicio de Cuidados Intensivos Pediátricos, Hospital General Universitario Gregorio Marañón de Madrid, Instituto de Investigación sanitaria del Hospital Gregorio Marañón, Madrid, Spain

<sup>b</sup> Red de Salud Maternoinfantil y del Desarrollo (RedSAMID), RETICS financiada por el PN I+D+I 2008-2011, ISCIII - Evaluación y Fomento de la Investigación y el Fondo Europeo de Desarrollo Regional (FEDER), Madrid, Spain

<sup>c</sup> Division of Pediatrics, Department of Women's and Children's Health - University of Padua, Padua, Italy

<sup>d</sup> Departamento de Salud Pública y Maternoinfantil, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

\* Corresponding author.

E-mail addresses: [laura\\_bl@hotmail.com](mailto:laura_bl@hotmail.com),  
[laura.butragueno@salud.madrid.org](mailto:laura.butragueno@salud.madrid.org)  
(L. Butragueño Laiseca).

<https://doi.org/10.1016/j.anpede.2021.06.007>

2341-2879/ © 2021 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## SARS-CoV-2 and prematurity. Any evidence of vertical transmission? ☆



### SARS-CoV-2 y prematuridad. ¿Existe evidencia de transmisión vertical?

Dear Editor,

Infection by the novel coronavirus (SARS-CoV-2) initially detected in 2019 in Wuhan, China, is the causative agent of the coronavirus disease 2019 (COVID-19), currently responsible of a global pandemic with significant repercussions in Spain.

Vertical transmission of SARS-CoV-2 remains unknown to date. Different authors have suggested that SARS-CoV-2 may be transmitted in utero, but it is not clear whether transmission occurs by crossing the placenta, through the birth canal or during the immediate postpartum period.<sup>1</sup> Isolated case reports, case series<sup>2,3</sup> and guidelines developed by experts of different scientific associations<sup>4,5</sup> have been published, with significant heterogeneity in the definition of vertical transmission, types of samples used for investigation and clinical manifestations documented in newborn infants.

We present the case of a preterm neonate born to a mother positive for COVID-19 that came to the emergency department after going into labour at 29+6 weeks of gestation. 9 days before delivery she had a positive result for SARS-CoV-2 antigen test in respiratory swab, performed on account of close contact with a positive case (household partner). Polymerase chain reaction (PCR) test from nasopharyngeal swab before delivery was positive. The mother was asymptomatic. She had a normal course of pregnancy and attended prenatal care visits, with normal ultrasound and laboratory outcomes. Drugs for tocolysis

and fetal lung maturation were administered, but it was not possible to stop preterm labour.

A male boy was born by vaginal delivery at 29+6 weeks, (1455 g birth weight) Intrapartum amniorrhexis. Apgar score 6/8. The preterm neonate required intubation at birth due to ineffective breathing, conventional mechanical ventilation and surfactant administration in the first hour of life. Chest radiograph revealed a bilateral reticular interstitial pattern suggesting neonatal respiratory distress syndrome. The neonate was admitted to the NICU into an individual room under contact and droplet isolation measures in the incubator, according to current recommendations.<sup>4,5</sup> Respiratory secretion samples obtained at birth and on day 3 were tested positive for SARS-CoV-2 using PCR, with low cycle threshold (Ct) values (Table 1). Blood test results were normal, without lymphopenia or increased inflammatory markers (Table 2). The patient was extubated on day 2 and exhibited improvement, with no symptoms other than apnoea of prematurity. Polymerase chain reaction tests in nasopharyngeal samples at 7, 12 and 15 days remained positive. Extended analytical study at 7th day revealed no evidence of increased systemic inflammatory markers (Table 2) except for D-dimer levels (4788.00 ng/mL). At 10 days, PCR blood test was negative with no detectable viral load in blood even viral shedding in urine and faeces was present. Results of antibody tests in the neonate (IgM and IgG) were persistently negative. The first negative PCR result from nasopharyngeal sample at 21 days allowed discontinuation of isolation measures. There was no evidence of seroconversion at 4 weeks post birth (Table 1).

During delivery, the mother wore a FFP2 mask. Skin-to-skin contact and delayed cord clamping were avoided. The neonate was fed with donor human milk initially, followed by artificial formula. Mother and child remained separated until the mother's quarantine could be lifted (positive IgG test), and the first mother-child visit took place 5 days after birth. However, tests were not performed for detection of the virus in the placenta, umbilical cord blood or amniotic fluid, so no definitive results could verify vertical transmission of SARS-CoV-2.

☆ Please cite this article as: Márquez Isidro EM, García García MJ, Solo de Zaldívar Tristancho M, Romero Peguero R. SARS-CoV-2 y prematuridad. ¿Existe evidencia de transmisión vertical? *An Pediatr (Barc)*. 2021;95:375–377.

**Table 1** SARS-CoV-2 test results.

|  | 2 h               | 1 day        | 3 days            | 7 days            | 10 days  | 12 days           | 15 days           | 21 days  | 33 days      |
|--|-------------------|--------------|-------------------|-------------------|----------|-------------------|-------------------|----------|--------------|
| PCR in nasopharyngeal secretion (Ct for gen S) | Positive (Ct: 35) |              | Positive (Ct: 20) | Positive (Ct :17) |          | Positive (Ct: 27) | Positive (Ct: 27) | Negative |              |
| PCR in bronchoalveolar lavage (Ct for gen S)   |                   |              | Positive (Ct: 36) |                   |          |                   |                   |          |              |
| Antibody testing                               |                   | IgM-<br>IgG- |                   |                   |          | IgM-<br>IgG-      | IgM-<br>IgG-      |          | IgM-<br>IgG- |
| PCR in blood                                   |                   |              |                   |                   | Negative |                   |                   |          |              |
| PCR in urine                                   |                   |              |                   |                   | Positive |                   |                   |          |              |
| PCR in faeces                                  |                   |              |                   |                   | Positive |                   |                   |          |              |

Ct, cycle threshold; PCR, polymerase chain reaction.

**Table 2** Laboratory variables.

|   | 2 h          | 1 day        | 7 days       | 15 days      | 33 days      |
|---|--------------|--------------|--------------|--------------|--------------|
| Leucocytes (cells/mm <sup>3</sup> )       | 5830         | 6710         | 11820        | 14180        | 6970         |
| Lymphocytes (cells/mm <sup>3</sup> ; %)   | 1780 (30.5%) | 1590 (23.7%) | 3590 (30.4%) | 5980 (42.2%) | 4010 (57.5%) |
| Neutrophils (cells/mm <sup>3</sup> ; %)   | 5170 (54.4%) | 4250 (63.4%) | 5140 (43.5%) | 4780 (33.7%) | 1390 (19.9%) |
| Platelets (cells/mm <sup>3</sup> )        | 147 000      | 209 000      | 202 000      | 516 000      | 384 000      |
| Prothrombin time (s)                      | 22           | 15           | 12           |              |              |
| Activated partial thromboplastin time (s) | 79           | 48           | 36           |              |              |
| Fibrinogen (g/dL)                         | 2            | 2            | 4            |              |              |
| D-dimer(ng/mL)                            |              |              | 4788         |              |              |
| CPR (mg/dL)                               | 0.02         | 0.14         | 0.04         |              |              |
| PCT (ng/mL)                               | 0.27         |              |              |              |              |
| AST (IU/L)                                | 65           | 56           | 27           | 22           | 22           |
| ALT (IU/L)                                | < 5          | < 5          | 6            | 11           | 11           |
| LDH (IU/L)                                | 642          |              | 561          | 330          | 291          |
| Ferritin (ng/mL)                          |              |              | 437          |              |              |
| Troponin T (ng/L)                         |              |              | 72.2         |              |              |
| NT-proBNP (pg/mL)                         |              |              | 915          |              |              |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPR, C-reactive protein; LDH, lactate dehydrogenase; NT-proBNP, N-terminal pro-hormone brain natriuretic peptide; PCT, procalcitonin.

In this article, we present the case of a neonate born before term to a mother with COVID-19 whose symptoms were most likely due to prematurity. The persistence of positive PCR results with low Ct values in the infant and the early timing of the first positive result suggest early infection. Although it is possible that the infant was infected in utero, this case is not sufficient to prove the possibility of vertical transmission.

The vertical transmission of SARS-CoV-2 is not well known. Although there have been reports of detection of the virus in the placenta, amniotic fluid, umbilical cord blood and human milk,<sup>6</sup> most of the SARS-CoV-2 tests conducted in neonates born to infected mothers are negative,<sup>3</sup> so data is inconclusive to prove vertical infection.

It is reasonable to conclude that vertical transmission of SARS-CoV-2 in infants born to mothers that are positive for the virus is possible and requires further research. Contact and droplet isolation measures should be implemented and maintained through the hospital stay until the PCR tests in respiratory secretion samples become negative, as seroconversion is rare in neonates, especially those born preterm.

## References

- Blumberg DA, Underwood MA, Hedriana HL, Lakshminrusimha S. Vertical transmission of SARS-CoV-2: what is the optimal definition? *Am J Perinatol.* 2020;37:769–72.
- Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. *Am J Obstet Gynecol.* 2021;224:35–53.

- Solís-García G, Gutiérrez-Vélez A, Pescador Chamorro I, Zamora-Flores E, Vigil-Vázquez S, Rodríguez-Corrales E, et al. Epidemiology, management and risk of SARS-CoV-2 transmission in a cohort of newborns born to mothers diagnosed with COVID-19 infection. *An Pediatr (Engl Ed).* 2021;94(3):173–8.
- Calvo C, López-Hortelano MG, Vicente JCC, Martínez JLV. Grupo de trabajo de la Asociación Española de Pediatría para el brote de infección por Coronavirus, colaboradores con el Ministerio de Sanidad; Miembros del Grupo de Expertos de la AEP. [Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group]. *An Pediatr (Barc).* 2020;92:241.
- Sociedad Española de Neonatología. Recomendaciones para el manejo del recién nacido en relación con la infección por SARS-CoV-2 Versión 6.2, 2020. [Accessed 14 February 2021]. Available from: <https://www.seneo.es/>.
- Fenizia C, Biasin M, Cetin I, Vergani P, Mileto D, Spinillo A, et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. *Nat Commun.* 2020;11:5128.

Elena María Márquez Isidro\*, María Jesús García García, María Solo de Zaldívar Tristancho, Rafael Romero Peguero  
*Servicio de Pediatría, Hospital San Pedro de Alcántara, Cáceres, Spain*

\* Corresponding author.

E-mail address: [elenamaria.marquez@salud-juntaex.es](mailto:elenamaria.marquez@salud-juntaex.es) (E.M. Márquez Isidro).

<https://doi.org/10.1016/j.anpede.2021.05.005>  
2341-2879/ © 2021 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## E-mail consultation assessment during COVID-19 pandemic<sup>☆</sup>



### Balance de la consulta por correo electrónico en la pandemia COVID-19

Dear Editor:

The COVID-19 has brought about a revolution in the doctor-patient relationship worldwide. The diagnosis, treatment, control and prevention of this infectious disease has become the top priority for health care workers and the general population.

In adherence with the protocols established by the Ministry of Health of Spain,<sup>1</sup> health care delivery should be preferentially remote to prevent potential transmission of the virus in health care settings. This has led to significant changes in work practices for health care professionals, and more limited access of patients to health services. In-person visits have been partly replaced by telemedicine.

During the pandemic, children were confined to the home between March 15 and April 26, 2020. In-person visits had to be agreed on by the provider and the patient, who have to decide whether care should be delivered in person or remotely.

Most patients with COVID-19 can be managed remotely,<sup>2</sup> but a large part of other health problems require in-person assessment.

The extensive use of the telephone as a vehicle for communicating with patients has made it harder to gain access to providers. Due to the preferential delivery of care through the telephone<sup>1,3</sup> and contact tracing and tracking of COVID cases from primary care centres, the phone lines are saturated. Based on the protocols imposed by the Ministry of Health,<sup>1</sup> COVID-19 patients and their contacts must be quarantined for a minimum of 10 days and monitored by the corresponding doctor every day.

In health care facilities where email has been used regularly for years, access to providers is more agile and health care users are familiarised with it.

In our primary care centre, 2 paediatricians and 2 paediatric nurses manage a caseload of 2400 children. The paediatric team uses a dedicated organizational email account. We offer email access to the entire catchment population. After 5 years, we have succeeded in establishing constant and sustained use of this means of communication. The second year after introducing email access, we

<sup>☆</sup> Please cite this article as: Peña Blasco G, Bartolomé Lalanza ML, Blasco Pérez-Aramendía MJ. Balance de la consulta por correo electrónico en la pandemia COVID-19. *An Pediatr (Barc).* 2021;95:377–378.